ABSTIL4ff. We investigated the effect of captopril, an orally active angiotensin converting enzyme inhibitor, on urinary protein excretion in puromycin aminonucleoside nephrotic rats. The administration of captopril(10 mg/100 g body weight) decreased proteinuria on days 10-14 following the administration of puromycin aminonucleoside (73.0 versus 125.0 rng, p c 0.01), without affecting glomerular filtration rate. The beneficial effect of captopril was not abolished by the continuous intravenous infusion of angiotensin I1 (10 pg/kg/h for 9 days) or subcutaneous injections of aprotinin (50,000 KIU/day for 3 days). Indomethacin, in moderate (5 mg/kg/day for 3 days) or high (10 mg/ kg/day) doses, abolished the captopril attenuation in urinary protein excretion. The salutory effect of captopril was characteized by a reduction in the fractional excretion of protein without compromising the glomerular filtration rate. No difference in renal ultrastructure was noted in captopril-treated versus control animals. Captopril was ineffective in reducing urinary protein excretion in rats with adriamycin-induced glomerulopathy. W e conclude that captopril acts to reduce proteinuria in renal disease states arising from depletion of the glomerular basement membrane polyanion. The mechanism of action is postulated to be an alteration in renal hemodynamics, namely increased blood flow and a decrease in the ultrafiltration coefficient, that are the consequence of increased intrarenal prostaglandin production. (Pediatr Res 19: 828-834, 1985) Abbreviations AI, angiotensin I AII, angiotensin I1 ACE, angiotensin converting enzyme BW, body weight FEpr, fractional excretion of protein G B M , glomeruiar basement membrane GFR, glomerular filtration rate ka ultrafiltration coefficient PAN, puromycin aminonucleoside Q A , renal blood flow Many vasoactive substances are capable of altering quantitative urinary protein excretion in normal and disease states.The
short-term infusion of AII into normal animals causes an increase in the fractional and absolute excretion of protein, provided the GFR is preserved (1-3). In contrast, indomethacin administration to patients with the nephrotic syndrome results in a parallel decline in absolute urinary protein excretion and GFR (4, 5) .
Captopril, an orally active ACE inhibitor, interacts with several important hormonal systems that control intrarenal hcmodynamics (6) . By virtue of its capacity to act as a converting enzyme inhibitor, this drug interferes with the conversion of A1 to AII. Under the name kininase 11, this same dipeptidase is responsible for the proteolytic inactivation of bradykinin, causing elevated blood kinin concentrations and increased urinary kinin excretion (7) . Captopril also acts, either directly or indirectly, to stimulate intrarenal prostaglandin synthesis and release. Each of these alterations, singly or in combination, might affect renal hemodynamic factors or intrinsic permselectivity properties of the glomerular capillary that influence macromolecular clearance (8, 9) . We, therefore sought to determine whether captopril could modify the degree of proteinuria observed in nephrotic rats and, if so, to elucidate its mechanism of action.
METHODS
Male Sprague-Dawley rats, weighing 125-275 g, were paired by weight and maintained in individual metabolic cages. They were fed ad I~bltum a diet of standard laboratory rat food. After a period of acclimatization to these conditions, 24-h urine samples were collected for 4 days to establish the baseline urinary protein and creatinine excretion rates. On day 5, both animals in each pair received a single intraperitoneal injection of PAN (Sigma Chemlcal Co., St. Louis, MO) 15 mg/100 g BW dissolved in 0.15 M saline. Inimediately after the administration of PAN, animals randomly assigned to the experimental group were started on captopril. The daily dose was 10 mg/100 g BW dissolved in 0.1 5 M saline and administered by oral gavage. Control animals received an equal volume of saline vehicle by the same route. Five successive protocols were performed and are described below (Fig. 1) .
Protocol I (n = 9 pairs): no additional drugs were administered.
The duration of study was 10 days following PAN administration.
Protocol II ( n = 5 pairs): all animals received a continuous infusion of A11 (Sigma), 10 ~g / 1 0 0 g BW/h, via intraperitoneally implanted osmotic minipumps (Alzet, Inc., Palo Alto, CA). The infusion commenced on day 6 (1 day post-PAN administration) and was maintained for 9 days.
Protocoi III (n = 5 pairs): all animals received aprotinin (Sigma) dissolved in a 5% dextrose solution, 50.000 kallikrein inhibitory units daily, administered subcutaneously in two divided doses (10) . The animals were studied for 7 days after the administration of PAN; aprotinin was given on the final 3 days. rng/kg BW/day. administered intraperitoneally in two divided doses. The animals were studied for 7 days following the administration of PAN; indomethacin was given on the final 3 days.
Protocol IVB ( n = 5 pairs): all animals received indomethacin dissolved in TRIS-HC1 buffer (pH 8), 10 mg/kg BW as a loading dose and then 10 mg/kg BW/day administered intraperitoneally in two divided doses. The animals were studied for 7 days after the administration of PAN; indomethacin was given on the final 3 days.
Protocol V (n = 4 pairs): nephrosis was induced by the intravenous administration of a single dose of adriamycin (Adria Laboratories Inc., Columbus: OH) 7.5 mg/kg BW. Experimental animals received captopril, 10 mg/100 mg BW/day by gavage, while control animals were given an equal volume of saline vehicle. No additional drugs were administered to these animals. The animals were studied for 14 days after the intravenous infusion of adriamycin. The animals were weighed and 24-h urine samples were collected daily for the duration of each protocol. Measurements of urinary protein and creatinine excretion were made on each sample. On the final day of study, the rats were sacrificed using pentobarbital anaesthesia, 50 mg/kg BW, given intraperitoneally. Serum samples were obtained for the determination of albumin and creatinine concentration. The kidneys were rapidly excised and portions placed in Dubosq-Brazil and cacodylate-buffered 2.5% glutaraldehyde solutions for fixation for light and electron microscopic examination, respectively. Thin sections were cut from paraffin-embedded material and stained with hematoxylin and eosin, periodic acid-Schiff, and Masson trichrome methods for light microscopy. Portions of the tissue for electron microscopy were postfixed in osmium tetroxide and stained with lead citrate and uranyl acetate. Ultrathin sections were cut from plastic embedded material and viewed with an electron microscope. Renal histological specimens were examined by a single pathologist (B.B.) who was blinded as to the protocol and experimental assignment of each animal.
Serum and urinary protein concentrations were determined spectrophotometrically (Guilford model) following sulfosalicylic acid precipitation (1 1). Serum and urinary sodium and potassium concentrations were measured with a flame photomet~:r with lithiurn as an internal standard. Serum and urinary crealinine concentrations were measured using the Jaffe reaction (12) .
The endogenous creatinine clerance was assumed to be equi valent to the GFR. The FEpr and creatinine clearance were calculated using standard formulas.
Statistical comparisons between experimental and control groups within each protocol were made using Student's paired t test. Multiple comparisons between groups were made using the Duncan multiple range test and an anlysis of variance. Results were considered statistically significant if p < 0.05.
RESULTS
The mean weight gain of the experimental and control animals was similar in all of the study protocols except in protocol 111, in which captopril-treated animals gained more weight than controls ( p < 0.01) (table 1). All animals became visibly edematous and developed moderate to marked degrees of ascites within 7 days of receiving PAN. No measurements of serum total protein, albumin, or cholesterol were made. Daily urine output and fluid intake tended to rise in parallel with the appearance of sustained heavy proteinuria in all animals studied. Each animal manifested at least a 2-fold rise above its baseline daily urinary protein excretory rate following the administration of PAN.
The results in protocol I are illustrated graphically in Figure 2 , in which mean daily protein excretion is plotted versus day.
There was no significant change in the mean daily urinaiy excretion during the first 3 days after the administration of PAN in either the control or experimental groups. However, on day 8 there was an abrupt onset of proteinuria in both groups. Ther'eafter, the mean daily protein excretion was significantly reduced on days 10--14 in the rats given captopril compared to their untreated counterparts ( p < 0.0 1).
The results obtained in protocol I1 and I11 are illustrated in Figures 3 and 4 . All of the animals that received the infusion (sf pharmacologic doses of A11 demonstrated a rise in proteinuria 1 day earlier (day 7) than the animals studied in protocol I. This discrepancy is a consequence of the AII-induced enhanceme~~t in the fractional and absolute excretion of macromolecules (2:). Thereafter, on days 9-13 experimental animals given captopril displayed a significant attenuation in protein excretion compared to control rats ( p < 0.05). A similar reduction in proteinuria was observed on days 8-1 1 ( p < 0.0 1) in experimental versus control rats given aprotinin. These observations imply that captop~il attenuation of proteinuria in PAN-nephrotic rats is not mediated via a reduction in the circulating levels of A11 or a potentiation of intrarenal bradykinin activity.
The results obtained in protocols IVA and IVB are illustrated in Figure 5 . In both studies, there was a rise in mean daily protein excretion on day 8, 4 days after PAN administration in experimental and control animals. However, on both the moderate and high dose indomethacin regimens, no significant differences in the daily excretion of protein were noted on days 9-1 I between Captopril experimental and control animals. Thus, systemic treatment with a prostaglandin synthesis inhibitor abolished any difference in mean daily urinary protein excretion between the two treatment groups. Animals given adriamycin to induce proleinuria demonstrated a gradual rise in urinary total protein excretion that was initially detected on day 5 after the intravenous injection and reaching a * * * * peak value by day 11. At no time during the 2-wk period of observation were any significant differences in mean daily protein excretion noted between captopril-treated and control animals (day 18: 144.9 i 8.3 mg/24 h captopril versus 169.
'The data obtained on the final day of study in each protocol namely, mean protein excretion, GFR, and FE,, are presented in Table 2 . The mean urinary protein excretion on the final day of study in the experimental and control animals reflected the pattern that had been established during the preceding 3-5 days within each protocol. There was no significant difference in the mean value for GFR between the captopril-treated and control animals in any drug treament group. The serum creatinine concentrations in experimental and control rats paralleled the respective GFR determinations ( (Fig. 6) . The magnitude and direction of the correlation coefficients changed in an analogous fashion in protocols I1 and 111, although the changes were not statistically significant in either instance. In marked contrast, in protocol IVA the correlation coefficients were +0.76 and +0.69 in experimental and control animals, respectively, while in protocol IVB the values were +0.67 and +0.7 1 (Fig. 6) . Using an analysis of variance, the differences in the correlation coefficients observed in protocols I and IV were statistically significant; no other comparisons were significantly different.
The FE,, was lower in captopril-treated rats compared to control counterparts in protocols 1-111 and V, although the difference vias statistically significant only in protocol 1 (0.022 +.
0.004, captopril-treated versus 0.035 + 0.005, control; p < 0.0 3).
Of note was the similar degree of reduction in the FE,, achieved by captopril treatment in protocols 1-111, i.e. 35%. FE,, was the same in experimental (0.008 + 0.003) and control animals (0.009 + 0.003) treated with indomethacin, 10 mg/kg BW/day; moreover, in animals treated with indomethacin, 5 mg/kg BW/day, the experimental group had a higher FE,, (0.033 & 0.01) cornpared to control animals (0.020 +. 0.004). Using the Dunc,an multiple range test, it was evident that the change in F13,, associated with captopril administration was significantly different in animals treated according to protocols IVA and IVB from those handled according to protocols I, 11, and 111. Thus, indornerhacin abolished the similar reduction in FE,, achieved by captopril treatment in protocols 1-111.
When samples of renal tissue were examined microscopically, all specimens showed fusion of epithelial cell foot processes and (12, 14, 15 (2, 10, 16. 17) . aprotinin (10, 18) , and indomethacin (19, 20) ( 10. 18, 19 (25) (26) (27) (28) . The consensus view is that the action o f captopril in reducing blood pressure cannot be entirely explained by its inhibition o f ACE. There is mounting evidence to suggest that captoprilinduced changes in prostaglandin production can better account for the drug's antihypertensive action in essential hypertension (26, 28) . Thus, the mechanism that we propose to explain the captopril attenuation in proteinuria in nephrotic rats is consonant with the pharmacological properties o f the drug and the vascular response to its administration in a different setting. Moreover, the postulated hemodynamic changes involve known intrarenal actions o f prostaglandins on QA and kf (23) .
used in this study are compatible with previously described usage, in the first instance, in both normal and nephrotic rats, and for the latter two drugs. in normal rats, In the case o f aprotinin and indomethacin, they are associated with a substantial reduction in urinary kinin and prostaglandin excretion in normal rats
Indirect evidence in favor o f this hemodynamic mechanism o f action for captopril may be gained by examining the drug effect in rats given adriamycin to induce nephrosis. Adriamycin causes proteinuria by altering the normal pore size distribution without affecting the GBM charge density (29, 30) . This is in contrast to the well-studied effect o f PAN which provokes proteinuria by depleting the glomerular capillary o f its electronegative siaPic acid residues (31, 32) . Deen and Satvat (33) (35) . It (34, 39) . Each o f these glomerulopathies is marked, in its incipient stages, by a normal or elevated GFR so that the response to captopmdl might be anticipated to be maximal (40 
